Boston Scientific (NYSE:BSX) said today that the European Patent Office revoked a patent owned by Edwards Lifesciences (NYSE:EW) in the latest round of their ongoing spat over transcatheter aortic valve replacements. In March 2017 a German court issued a mixed decision in the international battle over transcatheter aortic valve replacement patents between the two companies, less than a week after a […]
Boston Scientific acquires NVision Medical in $275m deal
Boston Scientific (NYSE:BSX) said today it inked a $275 million deal to acquire women’s health-focused NVision Medical, which produces an FDA-cleared device designed to collect cells from fallopian tubes as an early diagnosis of ovarian cancer. In the deal, Boston Scientific will pay $150 million up front with an additional $125 million in possible milestone payments […]
Boston Scientific pays $40m for remaining stake in Securus Medical
Boston Scientific (NYSE:BSX) said today that it paid $40 million for the stake in Securus Medical Group it didn’t already own and sweetened the pot with another $10 million in milestones. Back in September 2016, the Marlborough, Mass.-based medical device giant participated in a $10 million Series C round for Securus, which makes a thermal body mapping device for use […]
UPDATE: Boston Scientific touts win in UK-based patent spat with Edwards Lifesciences
Updated to include commentary from Edwards Lifesciences Boston Scientific (NYSE:BSX) said today it won a victory in a U.K.-based patent spat with Edwards Lifesciences (NYSE:EW), though Edwards argued that the win was a mixed bag. Marlborough, Mass.-based Boston Scientific said that the U.K. Court of Appeals dismissed an appeal from Edwards and upheld an earlier decision that […]
Boston Scientific lays off nearly 300 from Valencia neuromod facilities
Boston Scientific (NYSE:BSX) has laid off 289 employees at a facility near Los Angeles, according to a WARN report. The cuts, which were initially reported last November, went into effect on February 28, according to the report. The facility, located in Valencia, Calif., 40 miles north of Los Angeles, serves as the headquarters for the company’s […]
Second Sight Medical taps Blake as CFO | Personnel Moves – March 27, 2018
Second Sight Medical (NSDQ:EYES) said last week it named John Blake as its new chief financial officer, succeeding Thomas Miller who has held the position since 2014. Before joining Second Sight Medical, Blake acted as finance senior VP at Tyr Pharma, and has held positions with Volcano Corp and BD Biosciences, the company said. Blake worked with […]
Boston Scientific, Mayo Clinic back new Minneapolis medtech incubator
Boston Scientific (NYSE:BSX) is joining the Mayo Clinic and the University of Minnesota in backing startup accelerator Gener8tor as it launches a medtech focused incubator in Minneapolis, according to a new report from the Minneapolis Star Tribune. The newly launched accelerator will operate under a seven-week program that will support six new startups with a focus […]
Stent pioneer Jang wants Supreme Court to review royalty spat with Boston Scientific
Stent inventor and cardiologist Dr. David Jang is requesting a Supreme Court review of stent patent royalty spat he had with Boston Scientific (NYSE:BSX) related to a coronary stent. In the case, Dr. Jang claims that he developed a new coronary stent and patented it, then licensed it to Boston Scientific who agreed to pay him […]
Edwards Lifesciences touts win in transcath heart valve patent spat with Boston Scientific
Edwards Lifesciences (NYSE:EW) said late last week that the US Patent and Trademark Office ruled in their favor in a patent spat with Boston Scientific (NYSE:BSX) related to transcatheter heart valves. The Irvine, Calif.-based company said that the USPTO was engaged in an Inter Partes Review of a Boston Scientific US transcatheter heart valve patent, and ruled […]
UPDATE: Boston Scientific lays out $406m for NxThera which plans spin-out of cancer treatment tech
Updated with comments from NxThera president & CEO Bob Paulson. Boston Scientific (NYSE:BSX) said today that it laid out a $406 million deal for NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal calls for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in […]
Boston Scientific touts safety, effectiveness in Rhythmia mapping system study
Boston Scientific (NYSE:BSX) today released data from the True-HD study of its Rhythmia mapping system and Intellamap Orion mapping catheter, touting it as safe and effective to support treatments of arrhythmias. Results from the trial were presented at a late-breaking clinical trial session at the European Heart Rhythm Association’s annual congress in Barcelona, Spain. The 572-patient […]
- 1
- 2
- 3
- …
- 127
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+